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Introduction
Treatment decisions in breast cancer are informed not only by tumor grade, stage, and lymph node status, but also by genomic biomarkers, estrogen receptor (ER) and HER2.
Increasingly, multi-gene assays such as Oncotype DX and Mammaprint are being used in prognostic capacities for breast cancer patients (1, 2) . ER+ tumors have better overall prognosis and response to hormonal therapy, while ER-tumors are more aggressive, resistant to hormonal therapies, and frequently display elevated expression of growth factor receptors such as erbB family members, EGFR or HER2 (3) (4) (5) . Overexpression or amplification of HER2 occurs in approximately 25% of breast cancers, while EGFR overexpression occurs in up to 30% of breast cancers. Both are poor prognostic indicators independent of ER status; EGFR expression has an inverse correlation with ER and is more common in triple negative and basal breast cancers (6) , (7, 8) , while HER2 amplification tends to correlate with ER-negativity or lower levels of ER expression. Downstream effector pathways activated by erbB family signaling include the RAS/RAF/MEK/ERK, PI-3K/AKT/MTOR, and the MEKK1/SEK1/JNK pathways. Over the past decade, prominent roles for PI-3K/AKT/MTOR signaling in the biology of breast cancer have been established, in particular downstream of HER2 (ERBB2: gene product: HER2 protein product) signaling and in tamoxifen resistance mechanisms (9) (10) (11) .
We have previously examined the role of hyperactivation of ERK1/2 MAPK (hMAPK) occurring downstream of EGFR or HER2 in breast cancer. We established that hMAPK induces loss of ER expression, and that inhibition of hMAPK in ER-breast cancer cell lines and primary cultures from ER-breast tumors restores ER expression, suggesting that hMAPK plays a direct
Research. 8 role in establishing the ER-phenotype in breast cancer (12) (13) (14) . mRNA expression profiling of these hMAPK cell lines defined an "hMAPK gene expression profile" which strongly correlates with ER-status in clinical samples, establishing a link between hMAPK and the transcriptomes of ER-breast tumors (15) . microRNAs play critical regulatory roles in a wide range of biological and pathological processes, and microRNA expression profiling reveals substantial differences between cancer and normal tissue, and among different cancer types (16) (17) (18) . In the context of breast cancer, microRNA expression has been correlated with numerous biopathological features such as tumor grade, ER, PR, and HER2 status (19) (20) (21) , TP53 mutation status, or proliferation status (22) , and has also been used to classify the breast cancer subtypes identified by gene expression profiling (23) . microRNA expression studies have demonstrated the utility for microRNA profiles as disease classifiers and prognostic tools in breast cancer (24, 25) . Functional studies indicate that microRNAs regulate important genes and processes germane to breast cancer pathology, and are effectors of disease-associated signaling pathways (26) (27) (28) (29) (30) .
In the present study, we identify microRNAs associated with hyperactivation of ERK1/2 MAPK signaling and investigate their involvement in facilitating gene expression, adverse indicates that discrete signatures made up of subsets of these hMAPK-microRNAs are independently associated with increased risk of disease specific death and disease recurrence, particularly among patients with ER+ disease and in ER+ cancers treated with hormone therapy.
Materials and Methods
Clinical datasets
The following publicly available breast cancer datasets were used in this study: (34, 35) . Patient populations have been previously described in detail (22, (31) (32) (33) (34) (35) . Enerly and Lyng cohorts have previously been employed as validation or comparison datasets for identification of novel roles of microRNAs in breast cancer (35) (36) (37) (38) (39) (40) .
Gene and microRNA expression datasets
Gene and/or microRNA expression data for Buffa, Enerly, and Lyng datasets were retrieved from NCBI Gene Expression Omnibus. Gene expression, DNA copy number, RPPA protein expression, microRNA expression, and mutation status for breast cancers from the TCGA dataset were obtained using the CGDS-R package v 1.1.30. microRNA expression for the METABRIC dataset was retrieved from the European Genome-phenome Archive.
Signature generation and statistical analysis
Research. 
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mRNA expression and microRNA expression values were standardized by scaling expression of an individual mRNA/microRNA within each individual dataset to have mean 0, standard deviation 1. Buffa and TCGA datasets were used as training datasets for generating the hMAPK microRNA signature. Cancers from each dataset were classified as high-hMAPKmRNA or low-hMAPK-mRNA by Pearson's correlation to an idealized hMAPK mRNA signature as performed by Creighton et al. (15) . Briefly, for the ideal signature genes upregulated in the signature were given an arbitrary value of "1", and genes downregulated in the signature given an arbitrary value of "-1"; Pearson's correlation between the ideal signature and z-score standardized gene expression for breast cancers from the training and validation datasets were determined and cancers with positive Pearson's correlation were classified as "high-hMAPKmRNA" while cancers with negative Pearson's correlation were classified as "low-hMAPKmRNA".
MicroRNAs significantly differentially expressed (p ≤ 0.05) between breast cancers from training datasets classified as hMAPK-mRNA or not-hMAPK-mRNA were identified by student's t-test. P-values for expression differences between groups were permutation-adjusted by randomly assigning each sample to a group (creating a random group assignment for each sample) and performing a Student's t-test for between-group differences for each gene; this was repeated 1000 times, and the rank of the p-value for each individual gene from the nonpermuted analysis was divided by 1001, resulting in the permutation-adjusted p-value (for example: if a non-adjusted p-value of p=0.022 ranked 34 th lowest, the adjusted p-value would = 11 hMAPK-mRNA tumors and not-hMAPK-mRNA tumors from both the Buffa and TCGA training datasets comprised the total hMAPK-microRNA signature.
Correlation to ideal hMAPK-microRNA signature was performed for all available primary breast cancers from both training and validation datasets, as described for hMAPK-mRNA signature above. Differential mRNA expression between high-hMAPK-microRNA and lowhMAPK-microRNA cancers from TCGA training dataset, and likewise from METABRIC validation dataset, was analyzed by student's t-test.
MicroRNA target prediction was performed using the miRWalk database(40), a database that uses 10 different microRNA target prediction programs to identify putative microRNA targets. Genes were considered putative targets of hMAPK-microRNAs if they were predicted to be a target by 3 or more of the following prediction programs: DIANA-mt, miRanda, miRDB, miRWalk, RNAhybrid, PICTAR4, PICTAR5, PITA, RNA22, or TargetScan. Pearson's correlation of hMAPK-microRNA target expression to hMAPK-microRNA expression was performed to identify regulatory relationships that may differ between cancers classified as high-hMAPK-microRNA and those classified as low-hMAPK-microRNA. Standard statistical tests were performed, as described in supplemental methods. All statistical analyses were performed using R statistical software v 2.15.2 (43) . Microsoft Excel 2007 and R statistical software v 2.15.2 were used for figure generation. All t-tests performed were 2-sided.
To generate a hMAPK-microRNA recurrence signature, univariate analyses were first performed on the total hMAPK-microRNA signature to determine if expression of individual microRNAs (median cutoff) was associated with increased rate of disease recurrence in the Buffa training dataset. Breast cancers from the Buffa dataset were then partitioned into 2
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groups based on median expression of every hMAPK-microRNA on an individual basis. Using this grouping as a classifier, Kaplan-Meier survival curves were generated for disease recurrence, and logrank test p-values were determined; 22 microRNAs for which this logrank test p-value was ≤ 0.1 were included in the recurrence signature. Correlation to an ideal hMAPK-recurrence signature was determined as described above for mRNA signature analysis.
To generate an hMAPK-microRNA survival signature, primary Breast Cancers from the METABRIC dataset were first randomized into 2 populations. A leave-one-out analysis was then performed, sequentially removing single individual microRNAs from the hMAPK microRNA signature, and determining whether removal of each microRNA improved the ability of the signature to predict poor survival events in ER+ population at 5 years by Cox Proportional Hazards analysis, separately for each randomized population. The analysis was limited to the ER+ population due to the fact that the overwhelming majority of the ER-negative cancers were already classified as "high hMAPK". miRNAs whose removal improved the model in both randomized populations from the METABRIC dataset were tabulated. This randomization and leave-one-out analysis was repeated in 1000 random permutations of the dataset to ensure robustness and serve as a self-validation. MicroRNAs whose removal improved the model in more than 20% of randomizations were removed from the signature, establishing a 21-member refined hMAPK-microRNA signature. Correlation to an ideal hMAPK-microRNA survival signature was determined as described above for mRNA signature analysis.
microRNA expression array and qRT-PCR analysis
Research. We previously observed that the hMAPK-mRNA signature is present in a majority of ERbreast cancers and a small subset of ER+ breast cancers (13, 14) . We confirmed that the hMAPK-mRNA signature was similarly represented in the primary breast tumor datasets with paired mRNA-microRNA expression data analyzed in this study [The Cancer Genome Atlas breast cancer samples: "TCGA" (training cohort); Gene Expression Omnibus (GEO) GSE22220: "Buffa dataset" (training cohort); GEO GSE19536: "Enerly dataset" (validation cohort); METABRIC microRNA dataset: "METABRIC" (validation cohort); datasets previously described (22, 31, 32, 34, 35) ; clinical characteristics in Supplemental Table 1 ]. Tumors in each of these datasets classified as "high-hMAPK-mRNA" according to our hMAPK-mRNA signature (15) exhibited a significant association with ER-negativity in training and validation datasets ( Figure   1A ,1B). hMAPK-mRNA classification associated with a trend towards increased incidence of disease recurrence in the training dataset ( Figure 1C) , and increased incidence of disease recurrence and poorer disease-specific survival in the validation datasets ( Figure 1D ).
Generation and characterization of a breast cancer hMAPK-microRNA signature
Research. Figure 1 for study overview), establishing a 57 member hMAPK-microRNA signature (Supplemental Table 2 ). Primary breast cancers from training and validation datasets were classified as "high-hMAPK-microRNA" or "low-hMAPK-microRNA" according to this microRNA signature. To confirm that this hMAPK-microRNA signature identifies tumors with activated ERK1/2 MAPK signaling, we analyzed the expression of several genes regulated by ERK1/2 in breast cancer in the TCGA training cohort. Genes known to be downregulated by 
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expression data revealed significant differences in expression and phosphorylation of numerous proteins between high-hMAPK-microRNA and low-hMAPK-microRNA tumors, including proteins involved in or regulated by ERK1/2 MAPK signaling, as well as EMT proteins, protein markers of basal-like breast cancer, and proteins involved in mediating tamoxifen resistance (Supplemental Table 3 ).
To study the impact that altering MAPK signaling has on miRNA expression in established models of hyperactive MAPK signaling in breast cancer we altered MAPK signaling in our stable hMAPK cell lines (15) overexpressed hMAPK-microRNAs significantly decreased following abrogation of MAPK signaling with U0126 treatment (hsa-miR-221, hsa-miR-222) or increased following EGF treatment (hsa-miR-378). Likewise, underexpressed hMAPK-microRNAs were increased following abrogation of MAPK signaling with U0126 treatment (hsa-let-7a, hsa-miR-30a, hsamiR-30a*,hsa-miR-125a-5p, hsa-miR-375) or decreased following EGF treatment (hsa-let-7a, hsa-let-7e, hsa-miR-29c, hsa-miR-30c), indicating that these microRNAs are regulated by MAPK signaling. We observed that target genes of these validated hMAPK-microRNAs are hMAPK-microRNAs associated with recurrence identify a hMAPK-microRNA recurrence signature By limiting the signature to microRNAs whose individual expression was significantly associated with reduced recurrence-free survival on univariate analysis among patients from the Buffa training dataset, we identified a 22 member hMAPK-microRNA recurrence signature (Supplemental Table 4 
Multivariate Analysis of hMAPK-microRNA recurrence signature
Multivariate analysis of the hMAPK-microRNA recurrence signature in the METABRIC dataset using Cox Proportional Hazards analyses revealed that among all patients, high-hMAPKmicroRNA status is associated with a significant increase in risk of breast cancer specific death within 5 years from diagnosis (multiplicative hazard factor: 1.48, 95% CI: 1.002-2.175, p-value = 0.04886, Supplemental Table 5A ). Because we observed that classification as high-hMAPKmicroRNA by the hMAPK-microRNA recurrence signature was significantly associated with poor outcome in ER+ breast cancers, and ER+ breast cancers displayed a large variation in correlation Table 5B ).
Similarly, incremental increased Pearson correlation with the ideal hMAPK-microRNA recurrence signature is also associated with a significant incremental increase in risk of breast cancer specific death within 5 years from diagnosis among patients with ER+ cancer receiving hormone therapy, either alone or in conjunction with chemotherapy or radiotherapy (multiplicative hazard factor: 1.008, 95% CI = 1.002-1.014, p-value = 0.006285, Supplemental Table 5C ). Multivariate analysis of the Lyng ER+ cohort indicated a significant association with high-hMAPK-microRNA status according to the hMAPK-microRNA recurrence signature and increased risk of disease recurrence within 5 years (multiplicative hazard factor: 2.109, 95% CI = 1.1992-3.7085, p-value = 0.009583, Supplemental Table 5D ). Additionally, multivariate analysis indicated that increased Pearson correlation with the ideal hMAPK-microRNA recurrence signature associates with a significant increase in risk of breast cancer specific death within 5 years from diagnosis among ER+ patients from METABRIC dataset stratified by adjuvant therapy Table 1) .
In order to validate this hMAPK-microRNA ER+ survival signature, we assessed its association to disease survival in all patients and patients with ER+ disease in the Enerly dataset (p= 0.00689, 0.0538, respectively)( Figure 5C ). We additionally assessed association of this survival signature with disease recurrence in all patients and patients with ER-positive disease in the Buffa (p= 1 e-07, 0.000245, respectively)( Figure 5D ) and Enerly datasets (p= 0.00393, 0.0167, respectively)( Figure 5D ), and in ER+ patients treated with tamoxifen monotherapy from the Lyng dataset (p = 0.0371)( Figure 5B ). This survival signature was vastly superior to the total hMAPK-microRNA signature, and performed comparably to or better than the hMAPKrecurrence signature in the ability to predict poor outcome in patients classified as "highhMAPK" vs "low-hMAPK", even in the smaller publicly available datasets. This strongly suggests 
Discussion
Using paired mRNA and microRNA expression data from primary breast tumor datasets (TCGA, Buffa), we report a microRNA signature that associates significantly with the ERK1/2 hMAPK-mRNA expression signature. Classification of primary breast cancers using this hMAPKmicroRNA signature indicates significant association with ER negative status, high tumor grade, increased proliferation, basal and HER2 molecular subtypes, and poor clinical outcomes. This signature identifies a population of ER+ primary breast cancers classified as high-hMAPKmicroRNA that not only exhibit gene expression patterns similar to ER-primary breast cancers, but also exhibit significantly poorer clinical outcomes than ER+ cancers classified as lowhMAPK-microRNA. These observations were validated in independent, publicly available cohorts (Enerly, METABRIC). We report a subsignature composed of 22 microRNAs, an hMAPKmicroRNA recurrence signature, which retains significant associations with poor clinical outcome among breast cancer patients and significantly associates with poor response to hormone therapy in two independent validation datasets by multivariate analysis (Lyng and METABRIC datasets). Finally, we report a subsignature of this hMAPK-microRNA signature, consisting of 21 microRNAs, that is significantly associated with poorer disease-specific survival outcome in patients with ER-positive disease; an hMAPK-microRNA survival signature. 
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The hMAPK-microRNA signature (Supplemental Table 2 ) contains numerous microRNAs with previously reported roles in breast cancer etiology. Several hMAPK-microRNAs are significantly differentially expressed between basal/HER2+ subtype and Luminal A type cancers, between ER-and ER+, and between high grade vs low grade cancers (overexpressed: hsa-miR-150, -142-3p, -142-5p, -148a, -155, -135b; underexpressed: hsa-miR-30a-3-, -30a-5p, let-7a, -342) (35) . miR-29c, underexpressed in the hMAPK-microRNA signature, correlates with expression of GATA3, a luminal identity promoting transcription factor, and the miR-29 microRNA family facilitates GATA3 mediated maintenance of luminal identity (44) . The let-7 family of microRNAs, underexpressed in the hMAPK-microRNA signature, negatively regulates
RAS(45), and represses self-renewal and tumorigenicity of breast cancer stem cells (30). The
EMT-promoting transcription factor SNAI1 has been shown to be a direct target of miR-30a (46) . Overexpression of the hMAPK-downregulated microRNAs miR-29c, miR-30c, and miR-342 has been reported to significantly associate with good prognosis (35), and we observe significantly lower expression of GATA3 as well as miR-29c in ER+ tumors classified as hMAPKmicroRNA, and higher expression of basal markers and genes associated with poor clinical outcome, suggesting poor outcomes associated with these tumors may be due to loss of luminal identity and acquisition of ER-negative characteristics. A number of microRNAs upregulated in the hMAPK-microRNA signature (miR-142-5p/3p, miR-146a, miR-150, and miR- A number of hMAPK-microRNAs regulate the estrogen receptor (28-30, 47, 48) . The hMAPK-upregulated miR-221/222 family is overexpressed in ER-cancers (49), directly targets ER (49) , is upregulated in HER2 amplified versus non-amplified breast cancers (29) , and mediates tamoxifen resistance in MCF-7 cells by repression of CDKN1B, a cell cycle regulator that is underexpressed in breast cancers classified as high-hMAPK by our microRNA signature (see figure 2) (28, 29) . Six underexpressed microRNAs in the hMAPK-microRNA signature (hsamiR-125a, -let7e, -30d, -30a-5p, -30a-3p, -149) are underexpressed in treatment naïve ER+ primary cancers which expressed lower ESR1 mRNA levels, higher ERBB2 mRNA levels, and which had higher proportions of basal and HER2 subtype tumors than ER+ tumors with higher expression of these microRNAs (50) . Elevated expression of miR-30 family members (hsa-miR30a, -3p, -30c) is significantly associated with tamoxifen sensitivity (51) Focusing the analysis on the 12 microRNAs in common between the hMAPK-recurrence and hMAPK-survival microRNA signatures reduced the ability to prognosticate increased disease recurrence and decreased disease survival in all patient cohorts compared to the recurrence and survival signatures, but was still more significant than the total 57-member hMAPK microRNA signature (data not shown). This suggests that, while there are hMAPKmicroRNAs common to both the recurrence and the survival signature that may be useful biomarkers or potential drivers of general poor outcome (i.e low expression of miR-29c, miR-30
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family, high expression of 221/222, etc), alterations in particular hMAPK-microRNAs associate specifically with either increased disease recurrence or poor disease-specific survival (i.e-in the survival signature miR-22 and miR-224 are overexpressed, while let-7a is underexpressed), especially among ER-positive breast cancers.
The data presented here suggest that molecular and behavioral characteristics of tumors with activated growth factor signaling through the ERK1/2 MAPK axis are in part coordinated by aberrant microRNA expression associated with such activated MAPK signaling.
The reported functions of members of the hMAPK-microRNA signature, together with the survival and recurrence data from the Enerly, METABRIC, and Lyng validation datasets ( Figure   4 ,5, Table 1 ), suggest that the microRNAs identified in our hMAPK-microRNA signature contribute to endocrine resistance associated with activated ERK1/2 MAPK signaling, and raise the provocative possibility that the microRNAs contained within this signature may ultimately prove to have value as prognostic indicators of clinical outcome and as predictors of ER+ breast cancers with de novo endocrine resistance. These findings support further evaluation of the predictive potential of members of this hMAPK-microRNA signature for hormone therapy resistance and suggest that a subset of these microRNAs may also prove to be potential therapeutic targets. The identification of sub-signatures of hMAPK-microRNAs that significantly associate with increased disease recurrence and reduced disease-specific survival outcomes, particularly in patients with ER+ breast cancer, indicates that stratification of patients according to expression of these microRNAs may ultimately provide important information related to disease prognosis and response to therapy; these data indicate that the clinical application of these signatures warrants further investigation prospectively in large patient cohorts where Table 1 Multivariate analysis of hMAPK-microRNA survival signature in METABRIC dataset. 
